Merck may consider settling some Vioxx suits

Share this article:
Merck said it may consider settling a small number of Vioxx cases with patients who claim they were harmed and fit a narrow profile.
Merck's general counsel said that the company has not changed its defense strategy of fighting every case in court, according to a report in The Wall Street Journal. However, in cases where patients took Vioxx for more than 18 months and had no other risk factors for heart attacks or strokes, "we're going to have to carefully look at those cases," a Merck spokeswoman told the Journal.
The statement suggests for the first time that a settlement in a small number of cases may be part of Merck's plan and came less than a week after the company lost the first Vioxx case to go to trial. 
It is not known how many people took Vioxx daily for more than 18 months and who also had no other heart risk factors.
The tally of state and federal suits over Vioxx has climbed to 4,951 as of Aug. 15 – up from approximately 4,295 cases as of July 11.
Merck's next Vioxx trial is slated to begin Monday in state court in New Jersey.
The first federal Vioxx trial is set for Nov. 28, with trials to follow in February, March and April.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.